Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

@article{Leonardi2008EfficacyAS,
  title={Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)},
  author={C. Leonardi and A. Kimball and K. Papp and N. Yeilding and C. Guzzo and Yuhua Wang and Shu Li and L. T. Dooley and K. Gordon},
  journal={The Lancet},
  year={2008},
  volume={371},
  pages={1665-1674}
}
BACKGROUND Interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We assessed ustekinumab, a human monoclonal antibody directed against these cytokines, for the treatment of psoriasis. METHODS In this phase III, parallel, double-blind, placebo-controlled study, 766 patients with moderate-to-severe psoriasis were randomly assigned to receive ustekinumab 45 mg (n=255) or 90 mg (n=256) at weeks 0 and 4 and then every 12 weeks; or placebo (n=255) at weeks 0 and 4, with… Expand
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
TLDR
Intensification of dosing to once every 8 weeks with ustekinumab 90 mg might be necessary to elicit a full response in patients who only partially respond to the initial regimen. Expand
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
TLDR
Ustekinumab significantly reduced signs and symptoms of psoriatic arthritis and diminished skin lesions compared with placebo, and the drug was well tolerated. Expand
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
TLDR
Ustekinumab induced a clinical response in patients with moderate-to-severe Crohn's disease, especially in patients previously given infliximab. Expand
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled,
TLDR
The interleukin-12/23 inhibitor ustekinumab (45/90 mg q12 weeks) yielded significant and sustained improvements in PsA signs/symptoms in a diverse population of patients with active PsA, including anti-TNF-experienced PsA patients. Expand
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).
TLDR
Treatment with subcutaneous ustekinumab 45mg offers a favorable benefit/risk profile for Taiwanese and Korean patients with moderate-to-severe psoriasis and the efficacy and safety profile is consistent with the global phase III studies of usteksoniazid treatment for latent tuberculosis. Expand
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
TLDR
Itolizumab is an effective and well-tolerated novel biological therapy in moderate to severe psoriasis and the incidence of infections was not greater than placebo. Expand
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
TLDR
A high proportion of patients responded to ixekizumab therapy and maintained clinical responses over 1 year of treatment with no unexpected safety signals. Expand
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.
TLDR
Higher numbers of the following adverse events (AEs) of interest were observed with briakinumab during the placebo-controlled period, suggesting the need for surveillance for these events: serious infections, nonmelanoma skin cancers, and major adverse cardiovascular events. Expand
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
TLDR
Treatment with ustekinumab or guselkumab did not significantly reduce the signs and symptoms of RA and no new safety findings were observed with either treatment. Expand
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
TLDR
Ustekinumab significantly improved active psoriatic arthritis compared with placebo, and might offer an alternative therapeutic mechanism of action to approved biological treatments. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
TLDR
ABT-874, an interleukin 12/23 monoclonal antibody, was highly effective and well tolerated in the treatment of psoriasis and long-term studies are required to confirm these findings. Expand
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis
TLDR
A single SC administration of IL‑12/23 mAb was well tolerated and showed clinical response in subjects with moderate-to-severe psoriasis and interpretation of results is limited due to the small sample size. Expand
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
TLDR
This double-blind, placebo-controlled trial demonstrates the therapeutic efficacy of an interleukin-12/23 monoclonal antibody in psoriasis and provides further evidence of a role of the interleUKin- 12/23 p40 cytokines in the pathophysiology of Psoriasis. Expand
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.
TLDR
Dose-dependent associations with both the rate and extent of clinical response were observed across the four dose groups, and significant and sustained concentration-dependent improvements in psoriatic lesions were observed in most subjects. Expand
Severe psoriasis--oral therapy with a new retinoid.
TLDR
Ro 10--9359 proved to be an extremely potent antipsoriatic drug and a more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment. Expand
Interleukin-12, interleukin-23, and psoriasis: current prospects.
TLDR
IL-12 p40 antibody was well tolerated in a phase I clinical trial with few adverse events and substantial improvements in psoriasis in most individuals, and there was dose-dependent efficacy and substantial improvement in a larger cohort of patients in aphase II clinical trial. Expand
The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder
TLDR
The authors critically re-evaluated the view of psoriasis pathogenesis and postulate that in the majority of patients the T1 cells do not play a dominant role in the clinical, visible stage of this disease. Expand
Biological therapies in the systemic management of psoriasis: International Consensus Conference
TLDR
The limitations of current Psoriasis therapies, the value of biological therapies for psoriasis, and guidance regarding the incorporation of Biological therapies into clinical practice are discussed. Expand
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.
TLDR
PASI 50 equates to a clinically meaningful improvement in psoriasis and represents a discerning primary endpoint, according to histologic and photographic parameters of clinical trials of alefacept, efalizumab, and etanercept. Expand
...
1
2
3
4
5
...